General notice from NINDS: [Improving the Quality of NINDS-Supported Preclinical and Clinical Research through Rigorous Study Design and Transparent Reporting ][1] Some PARs/RFAs from NINDS: *(PAR is Program Announcement with special receipt, referral and/or review considerations, as described in the PAR announcement)* [NINDS Phase III Investigator-Initiated Efficacy Clinical Trials (U01)][2] [NINDS Exploratory Clinical Trials (R01)][3] [Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33) ][4] General notice from NIDA: [NIDA Notice: Improving Reporting of Research Methods and Results in Translational Addiction Research Involving Animals is a NIDA Commitment ][5] NICHD PAR: [Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01)][6] [1]: http://grants.nih.gov/grants/guide/notice-files/NOT-NS-11-023.html [2]: http://grants.nih.gov/grants/guide/pa-files/PAR-13-278.html [3]: http://grants.nih.gov/grants/guide/pa-files/PAR-13-281.html [4]: http://grants.nih.gov/grants/guide/pa-files/PAR-15-070.html [5]: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-14-007.html [6]: http://grants.nih.gov/grants/guide/pa-files/PAR-13-195.html